Feb 6 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP REACHES ENROLMENT TARGET FOR INSIGHT-003 TRIAL IN 1ST LINE NSCLC
- IMMUTEP LTD - ADDITIONAL DATA IS EXPECTED THROUGHOUT CALENDAR YEAR 2023 AND WILL FURTHER INFORM OUR NEXT STEPS IN 1L NSCLC
- IMMUTEP LTD - PROMISING INITIAL EFFICACY RESULTS SHOWING A 72.7% RESPONSE RATE AND 90.9% DISEASE CONTROL RATE REPORTED AT SITC 2022
News: IMM Immutep Reaches Enrolment Target For INSIGHT-003 Trial In 1st Line NSCLC
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.8¢ |
Change
0.028(12.0%) |
Mkt cap ! $370.6M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 25.8¢ | 23.3¢ | $536.0K | 2.165M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 209091 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 339100 | 18 |
View Market Depth
| Last trade - 14.15pm 15/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |